Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VGX-1027 · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| Group 1 | EXPERIMENTAL | 40mg QD dose group |
| Group 2 | EXPERIMENTAL | 100mg QD dose group |
| Group 3 | EXPERIMENTAL | 200mg QD dose group |
| Group 4 | EXPERIMENTAL | 200mg BID dose group |
| 1 | EXPERIMENTAL | 1mg dose group |
| 2 | EXPERIMENTAL | 10mg dose group |
| 3 | EXPERIMENTAL | 100mg dose group |
| 4 | EXPERIMENTAL | 200mg dose group |
| 5 | EXPERIMENTAL | 400mg dose group |
| 6 | EXPERIMENTAL | 800mg dose group |
| Name | Type | Description |
|---|---|---|
| VGX-1027 | DRUG | Subjects will |
Inclusion Criteria: * Must give written informed consent. * Healty subjects as determined by no clinically significant deviation from normal as judged by the investigator in medical history, physical examination, ECGs and clinical laboratory evaluations. * Body Mass Index (BMI) of 18 to 30kg/m2 ±0....
VGX-1027 is an investigational small molecule drug developed by Inovio Pharmaceuticals, Inc. It has been studied in Phase 1 clinical trials in healthy adult volunteers in the United States. Its therapeutic indications have not been publicly disclosed, and it remains in early clinical development rather than approved for any use.
VGX-1027 is being developed by Inovio Pharmaceuticals, Inc., which trades on the Nasdaq under the ticker INO. Inovio is the sponsor of the clinical program for this small molecule asset.
VGX-1027 is in Phase 1 development. Both of its recorded clinical trials were Phase 1 studies, and both have been completed. There are currently no active trials of VGX-1027, so the program is not presently enrolling or dosing patients.
VGX-1027 has been evaluated in two completed Phase 1 trials. NCT00627120 was a Phase 1 safety and pharmacokinetic study in 48 healthy subjects. NCT00760396 was a multiple-dose study in 40 healthy subjects. Both were conducted in the United States and together enrolled 88 participants.
Yes. The VGX-1027 Phase 1 program used a randomized, double-blind, controlled design. Both completed studies enrolled healthy adult volunteers aged 18 years and older, with enrollment of 48 subjects in NCT00627120 and 40 subjects in NCT00760396.
VGX-1027 is not an approved medicine. It is an investigational small molecule that has completed Phase 1 testing in healthy volunteers, and no later-stage trials or regulatory approvals have been recorded for it.